Philippe Laffont’s Nektar Therapeutics NKTR Stock Holding History

Philippe Laffont’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,475	Closed	-$478K	–	314
2019 Q4	$478K	Buy	+1,475	New	+$428K	﹤0.01%	233

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Philippe Laffont's NKTR Position: Q1 2020 in Review

Philippe Laffont sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 1,475 shares — an estimated $478K sold.

Philippe Laffont first reported a position in NKTR in Q4 2019 and held it in 1 quarter. The position peaked at $478K in Q4 2019. 244 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

Philippe Laffont reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
Philippe Laffont sold 1,475 Nektar Therapeutics shares in Q1 2020, an estimated $478K.
Philippe Laffont first reported a position in Nektar Therapeutics in Q4 2019 and held it in 1 quarter.
Philippe Laffont's Nektar Therapeutics position peaked at $478K in Q4 2019.
244 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Coatue Management's 13F filing for Q1 2020, filed 15 May 2020.